Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to June 2000

Can Silibinin Arrest Cancer Cell Growth?

June 2000


Altorjay I et al. The effect of silibinin on the free radical scavenger mechanisms of human erythrocytes in vitro. Acta Physiol Hung 1992;80:375-80.

Bialecka M. The effect of bioflavonoids and lecithin on the course of experimental atherosclerosis in rabbits. Ann Acad Med Stetin 1997;43:41-56.

Bindoli A et al. Inhibitory action of silymarin on lipid peroxide formation in rat liver mitochondria and microsomes. Biochem Pharmacol 1977;26:2405-9.

Boigk G et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997;26:643-9.

Bokemeyer C et al. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumor activity. Br J Cancer 1996;74:2036-41.

Chen H et al. Protective effects of silibinin and tetrandrine on the outcome of spontaneously hypertensive rats subjected to acute coronary artery occlusion. Int J Cardiol 1993;41:103-8.

Dehmlow C et al. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci 1996;58:1591- 1600.

Dehmlow C et al. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996;23:749-54.

Di Giulio AM et al. Inhibition of high glucose-induced protein mono-ADP-ribosylation restores neuritogenesis and sodium-pump activity in SY5Y neuroblastoma cells. J Neurosci Res 1999;57:663-9.

Feher J et al. Effect of silibinin on the activity and expression of superoxide dismutase in lymphocytes from patients with chronic alcoholic liver disease. Free Rad Res Commun 1987;3:373-7.

Feher J et al. Liver cell protection in toxic liver lesions. Acta Physiol Hung 1989;73:285-91.

Feher J et al. Liver-protective action of silymarin therapy in chronic alcoholic liver disease. Orv Hetil 1989;130:2723-7.

Ferenci P et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.
J Hepatol 1989;9:105-13.

Fuchs E et al. Effects of silibinin and of a synthetic analogue on isolated rat heptatic stellate cells and myofibroblasts. Drug Res 1997;47:1383-7.

Geller LI et al. Treatment of fatty hepatosis in diabetics. Probl Endokrinol (Mosk) 1993;39:20-2.

Germani E et al. Progressive and selective changes in neurotrophic factor expression and substance P axonal transport induced by perinatal diabetes: protection action of antioxidant treatment. J Neurosci Res 1999;57:521-8.

Gershbein LL. Action of dietary trypsin, pressed coffee oil, silymarin, and iron salt on 1,2-dimethylhydrazine tumorigenesis by gavage. Anticancer Res 1994;14:1113-6.

Gorio A et al. Endogenous mono-ADP-ribosylation in retina and peripheral nervous system. Adv Exp Med Biol 1997;419:289-95.

Gower JD et al. Prevention by antioxidants of oxidative damage to rabbit kidneys subjected to cold ischemia. Biochem Pharmacol 1989;38:213-15.

Kim DH et al. Silymarin and its components are inhibitors of beta-glucuronidase. Biol Pharm Bull 1994;17:443-5.

Kreeman V et al. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Med 1998;64:138-42.

Lahiri-Chatterjee M et al. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res 1999;59:622-32.

Locher R et al. Inhibitory action of silibinin on low density lipoprotein oxidation. Drug Res 1998;48:236-9.

Manna SK et al. Silymarin suppresses TNF-induced activation of NF-kappaB, c-Jun N-terminal kinase, and apoptosis. J Immunol 1999;163:6800-9.

Mira L et al. Scavenging of reactive oxygen species by silibinin dehemisuccinate. Biochem Pharmacol 1994;48:753-9.

Mowrey D. Guaranteed Potency Herbs: Next Generation Herbal Medicine. Keats Publishing, 1990.

Onat D et al. Effect of alpha-tocopherol and silibinin dihemisuccinate on the proliferation of human skin fibroblasts. Biotechnol Appl Biochem 1999;29:213-15.

Pietroangelo A et al. Antioxidant activity of silibinin in vivo during long-term iron overload in rats. Gastroenterology 1995;109:1941-9.

Rui YC et al. Effects of silibinin on production of oxygen free radical, lipoperoxide and leukotrienes in brain following ischemia and reperfusion. Chung Kuo 1990;11:418-21.

Saliou C et al. Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector silymarin in HepG2. Evidence for different activating pathways. FEBS Lett 1998;440:8-12.

Sanhuenza J et al. Changes in the xanthine dehydrogenase/xanthine oxidase ratio in the rat kidney subjected to ischemia-reperfusion stress: preventive effect of some flavonoids. Res Commun Chem Pathol Pharmacol 1992;78:211-8.

Scambia G et al. Antiproliferative effect of silibinin on gynecological malignancies: synergism with cisplatin and doxorubicin. European J Cancer 1996;32A:877-82.

Schonfeld J et al. Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity. CMLS Cell Mol Life Sci 1997; 53:917-20.

Schriewer H, Rauen HM. The effect of silibinin dihemisuccinate on cholesterol biosynthesis in rat liver homogenates. Arzneimittelforschung 1977;27:1691-4.

Skottova N, Krecman V. Silymarin as a potential hypocholesterolemic drug. Physiol Res 1998;47:1-7.

Skottova N, Krecman V. Dietary silymarin improves removal of low density lipoproteins by the perfused rat liver. Acta Univ Palacki Fac Med 1998;141:39-40.

Skottova N et al. Activities of silymarin and its flavolignans upon low density lipoprotein oxidizability in vitro. Phytother Res 1999; 13:535-7.

Sonnenbichler J et al. Biochemical effects of the flavonolignan silibinin on RNA, protein, and DNA synthesis in rat livers. Progress Clin Biol Res 1986;213:319-31.

Sonnenbichler J et al. Stimulatory effects of silibinin and silichristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther 1999;290:1375-83.

Strauber RE, Stindl G. Protective effect of silibinin against ethanol-induced cytotoxicity in HepG2 cells. J Hepatol 1999;30 (Suppl):277.

Soto CP et al. Prevention of alloxan-induced diabetes in the rat by silymarin. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998;119:125-9.

Tang ZJ. Alterations in insulin receptor in injured rats and the effects of dexamethasone and silibinin. Chung Hua 1991;7:214-7.

Valenzuela A et al. Selectivity of silymarin on the increase of glutathione content in different tissues of the rat. Planta Med 1989;55:420-2.

Valenzuela A et al. Effect of silibinin dihemisuccinate on the ethanol metabolizing systems of the rat liver. Cell Biochem Funct 1989;7:173-8.

Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and its structural isomer silibinin. Biol Res 1994;27:105-12.

Velussi M et al. Long-term (12 months) treatment with antioxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde in cirrhotic diabetic patients. J Hepatol 1997;26:871-9.

Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis 1999;20:2101-8.

Zhao J et al. Significant inhibition by the flavonoid antioxidant silymarin against 12_Otetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and coclooxygenase 2 and interleukin-1 alpha expression in SENCAR mouse epidermis: implications in the prevention of stage I tumor promotion. Mol Carcinog 1999;26:321-33.

Zi X et al. Novel cancer chemopreventive effects of silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem Biophys Res Commun 1997;239:334-9.

Zi X et al. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468; induction of G1 arrest through an increase in Cip1/p21concommitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res 1998;4:1055-64.

Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci USA 1999;96:7490-5.